Aprea Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference.
ByAinvest
Thursday, Aug 28, 2025 8:41 am ET1min read
APRE--
The presentation will provide an update on Aprea's mission to develop novel cancer therapies that target cancer cells directly while minimizing harm to healthy cells. This approach aims to eradicate tumors while reducing the risk of toxicity associated with conventional chemotherapy and other treatments. Aprea's lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications.
Aprea's investor relations website will serve as a platform for disclosing material nonpublic information and complying with Regulation FD disclosure obligations. The webcast link will be available on the Aprea Investors page under "News & Events" for 90 days.
About Aprea Therapeutics, Inc.
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells. The company's mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
References:
[1] https://www.globenewswire.com/news-release/2025/08/28/3140794/0/en/Aprea-Therapeutics-to-Present-at-H-C-Wainwright-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/APRE/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-yqnrncqbl43d.html
[3] https://www.stocktitan.net/news/APRE/
Aprea Therapeutics, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 3:30 PM ET. The presentation will be webcasted and available for 90 days on the company's Investors page. Aprea's mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones.
Doylestown, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel in New York. A webcast of the presentation will be accessible for 90 days through the company's investor relations website.The presentation will provide an update on Aprea's mission to develop novel cancer therapies that target cancer cells directly while minimizing harm to healthy cells. This approach aims to eradicate tumors while reducing the risk of toxicity associated with conventional chemotherapy and other treatments. Aprea's lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications.
Aprea's investor relations website will serve as a platform for disclosing material nonpublic information and complying with Regulation FD disclosure obligations. The webcast link will be available on the Aprea Investors page under "News & Events" for 90 days.
About Aprea Therapeutics, Inc.
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells. The company's mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
References:
[1] https://www.globenewswire.com/news-release/2025/08/28/3140794/0/en/Aprea-Therapeutics-to-Present-at-H-C-Wainwright-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/APRE/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-yqnrncqbl43d.html
[3] https://www.stocktitan.net/news/APRE/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet